<DOC>
	<DOC>NCT02303184</DOC>
	<brief_summary>A phase 2, multicenter, randomized, active-controlled, masked, parallel arm study designed to evaluate the safety and efficacy of a single suprachoroidal injection of CLS-TA, triamcinolone acetonide injectable suspension, given along with an intravitreal (IVT) injection of aflibercept compared to IVT aflibercept alone in subjects with retinal vein occlusion (RVO).</brief_summary>
	<brief_title>Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<criteria>diagnosis of macular edema following RVO History of ME â‰¤ 12 months 2070 letters inclusive BCVA using ETDRS has had an IVT injection of antiVEGF for RVO in the study eye has had a corticosteroid injection in the past 3 months in the study eye any uncontrolled ophthalmic condition in the study eye other than RVO</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>RVO</keyword>
	<keyword>ME</keyword>
	<keyword>Central Subfield Thickness</keyword>
	<keyword>OCT</keyword>
	<keyword>optical coherence tomography</keyword>
	<keyword>cystoid macular edema</keyword>
	<keyword>subretinal fluid</keyword>
	<keyword>Eylea</keyword>
	<keyword>aflibercept</keyword>
	<keyword>anti-VEGF</keyword>
</DOC>